MedTrace Logo

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

NCT00793182 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-03-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed tomography.

Conditions

  • Renal Impairment

Interventions

DRUG

Ioversol 320 mgI/mL

125 mL of Ioversol administered in the vein

DRUG

Iodixanol 320 mgI/mL

125 mL of Iodixanol administered in the vein

Sponsors & Collaborators

  • Guerbet

    lead INDUSTRY

Principal Investigators

  • Eddie Darton, MD · Mallinckrodt

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00793182 on ClinicalTrials.gov